Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Protagonist Therapeutics, Inc. PTGX
$25.03
+$0.31 (1.23%)
На 18:00, 12 мая 2023
+39.83%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1416969675.00000000
-
week52high
26.08
-
week52low
6.91
-
Revenue
26581000
-
P/E TTM
-10
-
Beta
1.95121100
-
EPS
-2.71000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 10:59
Описание компании
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | Overweight | 18 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 05 мая 2022 г. |
| BTIG | Buy | 11 февр 2022 г. | |
| JMP Securities | Market Outperform | Market Outperform | 15 ноя 2021 г. |
| JMP Securities | Market Outperform | Market Outperform | 13 окт 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 10 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Giraudo Bryan | A | 30000 | 30000 | 16 янв 2023 г. |
| Waddill William D. | A | 30000 | 30000 | 16 янв 2023 г. |
| Williams Lewis T | A | 30000 | 30000 | 16 янв 2023 г. |
| Noonberg Sarah B. | A | 30000 | 30000 | 16 янв 2023 г. |
| O'Dowd Sarah A | A | 30000 | 30000 | 16 янв 2023 г. |
| Ali Asif | A | 63750 | 63750 | 16 янв 2023 г. |
| Ali Asif | A | 24375 | 10625 | 16 янв 2023 г. |
| Gupta Suneel | A | 123750 | 123750 | 16 янв 2023 г. |
| Gupta Suneel | A | 138187 | 20625 | 16 янв 2023 г. |
| SELICK HAROLD E | A | 30000 | 30000 | 16 янв 2023 г. |
Новостная лента
Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm
Investors Business Daily
05 мая 2023 г. в 11:58
Shares of PTGX stock briefly broke out Friday after Protagonist said it plans to soon present new test results for its psoriasis drug. The post Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm appeared first on Investor's Business Daily.
Why Shares of Protagonist Therapeutics Rose This Week
The Motley Fool
20 апр 2023 г. в 21:51
Protagonist Therapeutics could become a buyout target. The company's lead therapy is coming off promising results as a cancer treatment.
Protagonist (PTGX) Up on Positive Results From FRONTIER Study
Zacks Investment Research
08 мар 2023 г. в 13:32
Protagonist (PTGX) gains as the phase II study, conducted by Janssen, achieves its primary goal.
Protagonist Therapeutics (PTGX) Moves 10.7% Higher: Will This Strength Last?
Zacks Investment Research
25 янв 2023 г. в 04:31
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
PRNewsWire
21 дек 2022 г. в 16:05
NEWARK, Calif. , Dec. 21, 2022 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V.